Literature DB >> 33384585

The Roles of High Mobility Group Box 1 in Cerebral Ischemic Injury.

Xiaoyun Gou1,2, Junjie Ying1,2, Yan Yue1,2, Xia Qiu1,2, Peng Hu1,2, Yi Qu1,2, Jinhui Li1,2, Dezhi Mu1,2.   

Abstract

High mobility group box 1 (HMGB1) is a ubiquitous nuclear protein that plays an important role in stabilizing nucleosomes and DNA repair. HMGB1 can be passively released from necrotic neurons or actively secreted by microglia, macrophages/monocytes, and neutrophils. Cerebral ischemia is a major cause of mortality and disability worldwide, and its outcome depends on the number of neurons dying due to hypoxia in the ischemic area. HMGB1 contributes to the pathogenesis of cerebral ischemia via mediating neuroinflammatory responses to cerebral ischemic injury. Extracellular HMGB1 regulates many neuroinflammatory events by interacting with its different cell surface receptors, such as receptors for advanced glycation end products, toll-like receptor (TLR)-2, and TLR-4. Additionally, HMGB1 can be redox-modified, thus exerting specific cellular functions in the ischemic brain and has different roles in the acute and late stages of cerebral ischemic injury. However, the role of HMGB1 in cerebral ischemia is complex and remains unclear. Herein, we summarize and review the research on HMGB1 in cerebral ischemia, focusing especially on the role of HMGB1 in hypoxic ischemia in the immature brain and in white matter ischemic injury. We also outline the possible mechanisms of HMGB1 in cerebral ischemia and the main strategies to inhibit HMGB1 pertaining to its potential as a novel critical molecular target in cerebral ischemic injury.
Copyright © 2020 Gou, Ying, Yue, Qiu, Hu, Qu, Li and Mu.

Entities:  

Keywords:  cerebral; high-mobility group box 1; ischemia; receptor for advanced glycation end products; therapeutic strategy; toll-like receptor

Year:  2020        PMID: 33384585      PMCID: PMC7770223          DOI: 10.3389/fncel.2020.600280

Source DB:  PubMed          Journal:  Front Cell Neurosci        ISSN: 1662-5102            Impact factor:   5.505


  131 in total

1.  Tissue specificity of nucleo-cytoplasmic distribution of HMG1 and HMG2 proteins and their probable functions.

Authors:  M I Mosevitsky; V A Novitskaya; M G Iogannsen; M A Zabezhinsky
Journal:  Eur J Biochem       Date:  1989-11-06

2.  Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways.

Authors:  H J Huttunen; C Fages; H Rauvala
Journal:  J Biol Chem       Date:  1999-07-09       Impact factor: 5.157

Review 3.  The NF-kappaB regulatory network.

Authors:  Allan R Brasier
Journal:  Cardiovasc Toxicol       Date:  2006       Impact factor: 3.231

4.  Protective effect of glycyrrhizic acid on cerebral ischemia/reperfusion injury via inhibiting HMGB1-mediated TLR4/NF-κB pathway.

Authors:  Sunhong Yan; Chuanqin Fang; Lei Cao; Long Wang; Jing Du; Yue Sun; Xuanxia Tong; Ying Lu; Xiaosan Wu
Journal:  Biotechnol Appl Biochem       Date:  2019-10-10       Impact factor: 2.431

5.  Induction and subcellular localization of high-mobility group box-1 (HMGB1) in the postischemic rat brain.

Authors:  Jung-Bin Kim; Chae-Moon Lim; Young-Mi Yu; Ja-Kyeong Lee
Journal:  J Neurosci Res       Date:  2008-04       Impact factor: 4.164

Review 6.  An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies.

Authors:  Domenica Musumeci; Giovanni N Roviello; Daniela Montesarchio
Journal:  Pharmacol Ther       Date:  2013-11-09       Impact factor: 12.310

7.  Maturing dendritic cells depend on RAGE for in vivo homing to lymph nodes.

Authors:  Angelo A Manfredi; Annalisa Capobianco; Antonio Esposito; Francesco De Cobelli; Tamara Canu; Antonella Monno; Angela Raucci; Francesca Sanvito; Claudio Doglioni; Peter P Nawroth; Angelika Bierhaus; Marco E Bianchi; Patrizia Rovere-Querini; Alessandro Del Maschio
Journal:  J Immunol       Date:  2008-02-15       Impact factor: 5.422

8.  Inhibiting HMGB1 Reduces Cerebral Ischemia Reperfusion Injury in Diabetic Mice.

Authors:  Chong Wang; Jie Jiang; Xiuping Zhang; Linjie Song; Kai Sun; Ruxiang Xu
Journal:  Inflammation       Date:  2016-12       Impact factor: 4.092

9.  Location, Location, Location: Appraising the Pleiotropic Function of HMGB1 in Fetal Brain.

Authors:  Martin G Frasch; Karen L Nygard
Journal:  J Neuropathol Exp Neurol       Date:  2017-04-01       Impact factor: 3.685

10.  HMGB1-triggered inflammation inhibition of notoginseng leaf triterpenes against cerebral ischemia and reperfusion injury via MAPK and NF-κB signaling pathways.

Authors:  Weijie Xie; Ting Zhu; Xi Dong; Fengwei Nan; Xiangbao Meng; Ping Zhou; Guibo Sun; Xiaobo Sun
Journal:  Biomolecules       Date:  2019-09-20
View more
  7 in total

Review 1.  A "Drug-Dependent" Immune System Can Compromise Protection against Infection: The Relationships between Psychostimulants and HIV.

Authors:  María Amparo Assis; Pedro Gabriel Carranza; Emilio Ambrosio
Journal:  Viruses       Date:  2021-04-21       Impact factor: 5.048

Review 2.  Dual Roles of Microglia in the Basal Ganglia in Parkinson's Disease.

Authors:  Mohammed E Choudhury; Yuka Kigami; Junya Tanaka
Journal:  Int J Mol Sci       Date:  2021-04-09       Impact factor: 5.923

3.  Clinical value of lncRNA TUG1 in temporal lobe epilepsy and its role in the proliferation of hippocampus neuron via sponging miR-199a-3p.

Authors:  Chunlian Li; Xiaojing Zheng; Pingping Liu; Meilian Li
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

Review 4.  Considerations about Hypoxic Changes in Neuraxis Tissue Injuries and Recovery.

Authors:  Simona Isabelle Stoica; Coralia Bleotu; Vlad Ciobanu; Anca Mirela Ionescu; Irina Albadi; Gelu Onose; Constantin Munteanu
Journal:  Biomedicines       Date:  2022-02-18

5.  Haptoglobin Regulates Macrophage/Microglia-Induced Inflammation and Prevents Ischemic Brain Damage Via Binding to HMGB1.

Authors:  Mayuka Morimoto; Takafumi Nakano; Saki Egashira; Keiichi Irie; Kiyoshi Matsuyama; Momoka Wada; Yoshihiko Nakamura; Yutaka Shigemori; Hiroyasu Ishikura; Yuta Yamashita; Kazuhide Hayakawa; Kazunori Sano; Kenichi Mishima
Journal:  J Am Heart Assoc       Date:  2022-03-04       Impact factor: 6.106

Review 6.  Toll-Like Receptor Signaling Pathways: Novel Therapeutic Targets for Cerebrovascular Disorders.

Authors:  Rezan Ashayeri Ahmadabad; Zahra Mirzaasgari; Ali Gorji; Maryam Khaleghi Ghadiri
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

7.  α-Synuclein evokes NLRP3 inflammasome-mediated IL-1β secretion from primary human microglia.

Authors:  Adrianne F Pike; Tatiana Varanita; Maaike A C Herrebout; Bonnie C Plug; Jeroen Kole; René J P Musters; Charlotte E Teunissen; Jeroen J M Hoozemans; Luigi Bubacco; Robert Veerhuis
Journal:  Glia       Date:  2021-01-28       Impact factor: 7.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.